Sandrock spent 23 years at Biogen, where he was head of R&D and chief medical officer.
Voyager gets $165 million upfront + up to $1.7 billion in potential milestone payments
$69 million upfront + up to $155 million in preclinical and Phase 1 options + up to $895 million in developmental milestones.
Company chart and information is provided by TradingView based on 15-minute-delayed data.
Voyager Therapeutics Inc is a clinical-stage gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. The company operates in a single segment of developing and commercializing gene therapies.
| Website: | www.voyagertherapeutics.com |
| Email: | pcox@vygr.com |
| Main Phone: | +1 857 259-5340 |
| Address: | 75 Sidney Street |
| State: | MA |
| City / Town: | Cambridge |
| Country: | US |
| Postal Code: | 02139 |
| Exchange: | NGS |
| CEO: | G. Andre Turenne |
| Employees: | 179 |
| NAICS: | Pharmaceutical Preparation Manufacturing(325412) |
Sandrock spent 23 years at Biogen, where he was head of R&D and chief medical officer.
Voyager gets $165 million upfront + up to $1.7 billion in potential milestone payments
$69 million upfront + up to $155 million in preclinical and Phase 1 options + up to $895 million in developmental milestones.
Voyager Therapeutics is developing targeted gene therapies for severe neurological diseases.
| Last Price N/A | Change $ N/A | Change % N/A | Tick N/A |
| Bid N/A | Bid Size N/A | Ask N/A | Ask Size N/A |
| Open N/A | High N/A | Low N/A | Prev Close N/A |
| Last Trade | Volume N/A | 52 Wk Hi N/A | 52 Wk Low N/A |
| Market Cap N/A | Ex-Div Date N/A | Div Rate N/A | Yield N/A |
| Shares N/A | EPS (TTM) N/A | PE Ratio N/A | Exchange N/A |
© 2022 Equities News | Equities.com, Inc.
* All dates and time are being displayed in Eastern Standard Time (EST).
